Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in connective, epithelial, and neural tissues. Exogenous formulations vary by route: intra-articular (IA) injections are cross-linked or high-molecular-weight polymers for viscoelastic supplementation, while topical and ophthalmic formulations serve as humectants or lubricants.
## Primary Indications
* **Intra-articular:** Osteoarthritis (OA) of the knee failing conservative therapy.
* **Ophthalmic:** Dry eye disease (keratoconjunctivitis sicca).
* **Dermatologic:** Facial aesthetic augmentation (dermal fillers) and skin hydration.
## Adult Dosing
* **IA Knee Injection (e.g., Euflexxa, Hyalgan, Orthovisc):** Dosing and frequency vary significantly by manufacturer product.
* *Standard:* 2 mL per knee once weekly for 3 to 5 weeks (depending on product viscosity).
* *Single-Dose formulations (e.g., Durolane, Monovisc):* 3 mL or 4 mL administered as a single IA injection.
* **Ophthalmic:** 0.1% to 0.4% solution; 1–2 drops in affected eye(s) as needed.
## Pediatric Dosing
There is no standard established systemic or IA pediatric dosing for HA. Use is generally restricted to topical or ophthalmic support by specialist recommendation.
## Dose Adjustments
* **Renal/Hepatic:** No adjustments necessary for local/IA administration.
* **Geriatric:** Use cautiously in patients with severe joint deformity or local skin infections.
## Contraindications
* Known hypersensitivity to hyaluronate or avian-derived proteins (for specific avian-sourced products).
* Active joint infection (e.g., septic arthritis), severe inflammation, or skin disease/infection in the injection site area.
## Adverse Effects
* **Intra-articular:** Transient pain/swelling (arthralgia), effusion, stiffness, and local injection site reaction. Rarely: pseudoseptic reaction (acute inflammatory response).
* **Ophthalmic:** Transient blurred vision, ocular irritation/stinging.
* **Dermatologic:** Bruising, redness, edema, or nodules at injection site.
## Key Drug Interactions
* **Quaternary Ammonium Compounds:** Do not use with benzalkonium chloride in ophthalmic solutions as it may cause precipitation.
* **Analgesics/NSAIDs:** No clinically significant systemic interactions; however, patients may temporarily decrease analgesic use post-IA injection.
## Monitoring
* **Intra-articular:** Monitor for signs of local infection (redness, warmth, fever) or severe inflammatory exacerbation post-injection.
* **Ophthalmic:** Continued symptoms of ocular dryness.
## Clinical Pearls
* **Selection:** Verify if the product is avian-derived (derived from rooster combs) or biosynthesized via bacterial fermentation, as this impacts allergy risk.
* **Effectiveness:** Evidence for IA-HA in knee OA is heterogeneous; it is often considered a "bridge" therapy rather than a primary disease-modifying treatment.
* **Injection Technique:** IA injection requires strict aseptic technique; ultrasound guidance is recommended to ensure intra-articular placement and improve efficacy.
* **Product Variance:** Do not interchange brands; each has unique cross-linking technology and regulatory approved dosing schedules.
***
**Educational Disclaimer:** This information is for educational purposes only. Hyaluronic acid products vary significantly by manufacturer and specific formulation. Always verify the current prescribing information package insert and adhere to your local institutional protocols before administration.
